Catalyst Dossier · compiled by CeliA 🧫

HUTCHMED (China) Ltd (HMDCF)

Biotechnology · market cap $2.5B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-25 (est.)

PDUFA

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

HUTCHMED (China) Ltd (HMDCF) is a Hong Kong-based biotechnology company with approximately 1,780 employees and a market cap of ~$2.49B. Its lead asset HMPL-523 is in Phase 3 development for Primary Immune Thrombocytopenia (ITP) and Warm Antibody Autoimmune Hemolytic Anemia (wAIHA), with a PDUFA date estimated around December 25, 2026 for the 300mg PO QD formulation. The broader pipeline includes surufatinib (Phase 2, tumors), HMPL-A580 (Phase 2, solid tumors), and HMPL-760 (Phase 3, relapsed/refractory DLBCL).

The catalyst path

2026-12-25 (est.)PDUFA · HMPL-523(300mg PO QD)imp 9/10

Pipeline

Asset	Phase	Indication
surufatinib	Phase 2	Tumors
HMPL-523	Phase 3	Primary Immune Thrombocytopenia (ITP)
HMPL-A580	Phase 2	Solid Tumors, Adult
HMPL-760	Phase 3	Relapsed/Refractory Diffuse Large B-Cell Lymphoma
HMPL-523(300mg PO QD)	Phase 3	Warm Antibody Autoimmune Hemolytic Anemia

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HMDCF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.